icon-folder.gif   Conference Reports for NATAP  
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
High Rates of SVR in Patients With Genotype 1 HCV Infection and Cirrhosis After Treatment With Ledipasvir/Sofosbuvir + Ribavirin or Ledipasvir/Sofosbuvir + GS-9669 for 8 Weeks
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Combination Oral, Ribavirin Free, Antiviral Therapy to Optimize Treatment Outcomes for Hepatitis C Treatment Naïve Patients: Interim Results from the NIAID SYNERGY Trial (6 & 12 weeks therapy).......http://www.natap.org/2013/AASLD/AASLD_30.htm ........100% who received the FDC+the protease (GS9451/Vedroprevir) for 6 weeks achieved SVR4
Sovaldi \ ledipasvir+vedroprevir Study in treatment-experienced gt1 cirrhotics - 8 weeks - (10/08/14)
Eric Lawitz,1 Fred Poordad,1 Robert H. Hyland,2 Jing Wang,2 Phillip S. Pang,2 William T. Symonds,2 John G. McHutchison,2 Fernando E. Membreno1 1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 2Gilead Sciences, Inc., Foster City, CA